Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Increased CD39 expression on CD4(+) T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia.

Perry C, Hazan-Halevy I, Kay S, Cipok M, Grisaru D, Deutsch V, Polliack A, Naparstek E, Herishanu Y.

Ann Hematol. 2012 Aug;91(8):1271-9. doi: 10.1007/s00277-012-1425-2.

PMID:
22349724
2.

Ectonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1/CD39) as a new prognostic marker in chronic lymphocytic leukemia.

Abousamra NK, Salah El-Din M, Hamza Elzahaf E, Esmael ME.

Leuk Lymphoma. 2015 Jan;56(1):113-9. doi: 10.3109/10428194.2014.907893.

PMID:
24684231
3.

CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia.

Pulte D, Furman RR, Broekman MJ, Drosopoulos JH, Ballard HS, Olson KE, Kizer JR, Marcus AJ.

Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):367-72. doi: 10.1016/j.clml.2011.06.005.

4.

CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia.

Pulte D, Olson KE, Broekman MJ, Islam N, Ballard HS, Furman RR, Olson AE, Marcus AJ.

J Transl Med. 2007 May 4;5:23.

5.

Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia.

Giannopoulos K, Schmitt M, Kowal M, Wlasiuk P, Bojarska-Junak A, Chen J, Rolinski J, Dmoszynska A.

Oncol Rep. 2008 Sep;20(3):677-82.

PMID:
18695923
6.
7.

[Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].

Kardum-Skelin I, Planinc-Peraica A, Ostojić Kolonić S, Radić-Kristo D, Milas M, Vrhovac R, Sustercić D, Minigo H, Jaksić B.

Acta Med Croatica. 2008 Oct;62(4):351-64. Croatian.

PMID:
19205412
8.

Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.

Nunes C, Wong R, Mason M, Fegan C, Man S, Pepper C.

Clin Cancer Res. 2012 Feb 1;18(3):678-87. doi: 10.1158/1078-0432.CCR-11-2630. Erratum in: Clin Cancer Res. 2012 Jul 1;18(13):3714.

9.

Surface profiles for subclassification of chronic lymphocytic leukemia.

Huang PY, Best OG, Belov L, Mulligan SP, Christopherson RI.

Leuk Lymphoma. 2012 Jun;53(6):1046-56. doi: 10.3109/10428194.2011.631370. Review.

PMID:
22023531
10.

Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia.

Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ, Wierda WG.

Leukemia. 2005 Oct;19(10):1788-93.

PMID:
16094420
11.

Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia.

Jadidi-Niaragh F, Ghalamfarsa G, Memarian A, Asgarian-Omran H, Razavi SM, Sarrafnejad A, Shokri F.

Tumour Biol. 2013 Apr;34(2):929-40. doi: 10.1007/s13277-012-0628-4.

PMID:
23269607
12.

CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.

Del Poeta G, Del Principe MI, Zucchetto A, Luciano F, Buccisano F, Rossi FM, Bruno A, Biagi A, Bulian P, Maurillo L, Neri B, Bomben R, Simotti C, Coletta AM, Dal Bo M, de Fabritiis P, Venditti A, Gattei V, Amadori S.

Haematologica. 2012 Feb;97(2):279-87. doi: 10.3324/haematol.2011.052829.

13.

High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease.

Wolowiec D, Wojtowicz M, Ciszak L, Kosmaczewska A, Frydecka I, Potoczek S, Urbaniak-Kujda D, Kapelko-Slowik K, Kuliczkowski K.

Eur J Haematol. 2009 Apr;82(4):260-6. doi: 10.1111/j.1600-0609.2008.01196.x.

PMID:
19187271
14.

Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.

Romano C, De Fanis U, Sellitto A, Dalla Mora L, Chiurazzi F, Giunta R, Rotoli B, Lucivero G.

Leuk Lymphoma. 2003 Nov;44(11):1963-71.

PMID:
14738151
15.

Abnormal T-cell function in B-cell chronic lymphocytic leukaemia.

Scrivener S, Goddard RV, Kaminski ER, Prentice AG.

Leuk Lymphoma. 2003 Mar;44(3):383-9. Review.

PMID:
12688308
16.

Intracellular tumor necrosis factor production by T- and B-cells in B-cell chronic lymphocytic leukemia.

Bojarska-Junak A, Rolinski J, Wasik-Szczepaneko E, Kaluzny Z, Dmoszynska A.

Haematologica. 2002 May;87(5):490-9.

17.

CXCL12 is a costimulator for CD4+ T cell activation and proliferation in chronic lymphocytic leukemia patients.

Borge M, Nannini PR, Morande PE, Jancic C, Bistmans A, Bezares RF, Giordano M, Gamberale R.

Cancer Immunol Immunother. 2013 Jan;62(1):113-24. doi: 10.1007/s00262-012-1320-7.

PMID:
22842611
18.

Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia.

Ibrahim S, Jilani I, O'Brien S, Rogers A, Manshouri T, Giles F, Faderl S, Thomas D, Kantarjian H, Keating M, Albitar M.

Cancer. 2003 Apr 15;97(8):1914-9.

19.

Phenotypic analysis of receptor-ligand pairs on B-cells in B-chronic lymphocytic leukemia.

Gagro A, Dasić G, Sabioncello A, Rabatić S, Reckzeh B, Havemann K, Kardum I, Jacksić B, Vitale B.

Leuk Lymphoma. 1997 Apr;25(3-4):301-11.

PMID:
9168440
20.

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé S, López-Guillermo A, Campo E, Montserrat E.

N Engl J Med. 2003 May 1;348(18):1764-75.

Items per page

Supplemental Content

Support Center